4.80
-0.62%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Honz Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 300086.SZ. It has been listed since 26 May 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥466.1m and a net loss of CN¥230.1m. At that date it held total assets of CN¥1.79bn and shareholders' equity of CN¥899.7m.
Honz Pharmaceutical Co., Ltd. engages in the manufacture and distribution of drugs for children. The company is headquartered in Haikou, Hainan. The company went IPO on 2010-05-26. The firm provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The firm's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 May 2010
- Employees
- 843
- Website
- honz.com.cn ↗
Leadership
Pay as last reported
- Mr. Jiangyou HongChairman of the Board, since 2019CN¥460,000
- Mr. Jiangtao HongPresident, since 2019CN¥324,800
- Ms. Liping HongVice Chairman of the Board, Vice President, since 2019CN¥331,000
- Ms. Jing LiChief Financial Officer
- Mr. Dexin LinVice President, Secretary of the BoardCN¥388,600
- Mr. Yong WangAssistant to Chairman of the BoardCN¥309,200
- Mr. Dongxiong HongDirector
- Mr. Guoyong LiDirectorCN¥66,000
- Mr. Youquan LiDirectorCN¥180,000
- Mr. Sidong ChenIndependent Director, since 2019
- Mr. Qinghe WuIndependent Director
- Mr. Jicheng ZhangIndependent Director, since 2019CN¥90,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Honz Pharmaceutical employs 843 full-time employees in Haikou, Hainan.
- The company manufactures pediatric drugs including nimesulide granules and Zhike Juhong granules.
- Honz offers both western medicines and Chinese patent drugs for children.
Weaknesses
- Honz Pharmaceutical's products include adult medications like Norfloxacin capsules.
- The company's business focuses on children's drugs without adult product expansion.
- Honz Pharmaceutical has no mention of international market presence in its description.
Opportunities
- Honz can expand into the Chinese pharmaceutical market with its pediatric drug portfolio.
- The company may leverage its Chinese patent drugs for domestic market growth.
- Honz Pharmaceutical could target the growing health care sector in Hainan.
Threats
- Honz Pharmaceutical faces competition from other Chinese pharmaceutical companies.
- The company's reliance on pediatric drugs may limit market diversification.
- Regulatory changes in the Chinese pharmaceutical industry could impact operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.